Specialties

New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.

In addition to psychosocial risk factors, disease related factors may also be contributing to bulimic symptoms.

Placing newborns in prospective studies to conduct genetic screenings with follow up may reduce the risk of DKA at diagnosis of type 1.

Dr. Matthew Weir discusses the pros and cons of SGLT-2 drugs with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine at the University of Maryland. Dr. …

Dr. Matthew Weir talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the impact of SGLT2 drugs on the possible improvement of kidney disease. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine …

At the the AACE 2017 convention in Austin, Texas, Dr. Matthew Weir and Diabetes in Control Publisher Steve Freed discuss the impact of SGLT2 drugs in helpful as well as possibly harmful ways. They also look at the need for safety studies for kidney disease. Dr. Matthew Weir, MD is …

At the AACE 2017 convention in Austin, Texas, Dr. Matthew Weir talks with Diabetes in Control Publisher Steve Freed about how he detects kidney disease in an effort to catch and treat the condition in its early stages. Dr. Matthew Weir, MD is a professor of medicine and director of …

Glucose peaks tied to greater cognitive decline for those with diabetes and A1c ≥7.0 percent.

Results showed that the intervention will be cost effective.

Results from the ongoing first large real-world evidence study of its kind published in the American Heart Association.